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Trends in survival after a diagnosis of heart failure in the United 
Kingdom 2000-2017: population based cohort study
Clare J Taylor,1 José M Ordóñez-Mena,1 Andrea K Roalfe,1 Sarah Lay-Flurrie,1 Nicholas R Jones,1 
Tom Marshall,2 F D Richard Hobbs1
AbstrAct
Objectives
To report reliable estimates of short term and long 
term survival rates for people with a diagnosis of 
heart failure and to assess trends over time by year 
of diagnosis, hospital admission, and socioeconomic 
group.
Design
Population based cohort study.
setting
Primary care, United Kingdom.
ParticiPants
Primary care data for 55 959 patients aged 45 
and overwith a new diagnosis of heart failure and 
278 679 age and sex matched controls in the Clinical 
Practice Research Datalink from 1 January 2000 to 
31 December 2017 and linked to inpatient Hospital 
Episode Statistics and Office for National Statistics 
mortality data.
Main OutcOMe Measures
Survival rates at one, five, and 10 years and cause 
of death for people with and without heart failure; 
and temporal trends in survival by year of diagnosis, 
hospital admission, and socioeconomic group.
results
Overall, one, five, and 10 year survival rates increased 
by 6.6% (from 74.2% in 2000 to 80.8% in 2016), 
7.2% (from 41.0% in 2000 to 48.2% in 2012), and 
6.4% (from 19.8% in 2000 to 26.2% in 2007), 
respectively. There were 30 906 deaths in the heart 
failure group over the study period. Heart failure 
was listed on the death certificate in 13 093 (42.4%) 
of these patients, and in 2237 (7.2%) it was the 
primary cause of death. Improvement in survival 
was greater for patients not requiring admission 
to hospital around the time of diagnosis (median 
difference 2.4 years; 5.3 v 2.9 years, P<0.001). There 
was a deprivation gap in median survival of 2.4 years 
between people who were least deprived and those 
who were most deprived (11.1 v 8.7 years, P<0.001).
cOnclusiOns
Survival after a diagnosis of heart failure has shown 
only modest improvement in the 21st century and lags 
behind other serious conditions, such as cancer. New 
strategies to achieve timely diagnosis and treatment 
initiation in primary care for all socioeconomic groups 
should be a priority for future research and policy.
Introduction
Heart failure is a common and costly clinical 
syndrome, but it can be treated effectively.1 2 A rise in 
cardiovascular risk factors, improved survival from 
ischaemic heart disease, and population ageing have 
contributed to a sustained increase in prevalence.3 
Recent analysis of primary care data in the United 
Kingdom found the absolute number of people living 
with heart failure increased by 23% between 2002 
and 2014 from 750 125 to 920 616 (1.4% of the 
population).4 The global economic cost of heart failure 
is estimated at US$108bn (£82.4bn; €94.5bn) per 
year, comprising direct costs to healthcare systems and 
indirect costs to society through loss of productivity. 
The greatest expenditure is in the last three months 
of life.5 6 Pharmacological treatments, devices, and 
exercise based rehabilitation can improve outcomes 
for patients, particularly those with heart failure with 
reduced ejection fraction, but diagnosis is crucial to 
allow timely initiation of evidence based treatments.
Reliable and contemporary survival estimates 
are important for any long term condition at the 
population level to monitor trends in prognosis and 
to commission appropriate services. At a patient 
level, these estimates allow informed discussions 
and shared decision making about treatment options 
and advanced care planning.7 Previous prognostic 
studies in heart failure have used data from hospital 
inpatients or screening studies to report survival. 
People with established heart failure who need to be 
admitted to hospital for acute decompensation have 
high mortality rates; up to one in six patients die 
during admission or within 30 days after discharge.8-10 
Survival for screen detected heart failure is more 
favourable, with around half of all study participants 
alive at five years.11 12 Studies of people diagnosed as 
having heart failure in a routine community setting 
are limited and inconsistent, and trends in survival 
over time are conflicting.13-15 Analysis of primary 
care records in The Health Improvement Network 
showed no change in survival after a diagnosis of 
heart failure between 1998 and 2012; this finding 
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survival trends over time are inconsistent
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This study provides estimates of short term and long term survival rates for 
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was received with some concern by the heart failure 
community and the wider public.13 Contemporary 
data are needed to establish if outlook has improved 
in recent years and to explore factors associated with 
worse outcome.
Charities, cardiology organisations, and government 
bodies have produced regional and country specific 
guidelines to inform evidence based practice with 
the aim of improving patient outcomes, but uptake is 
not universal.16 17 The National Heart Foundation of 
Australia and the National Institute for Health and Care 
Excellence in England have recently updated their heart 
failure guidelines with new recommendations. These 
guidelines include a focus on collaboration between 
primary and secondary care.18 19 However, within 
healthcare systems, heart failure has not received the 
same strategic focus and funding resources as other 
long term conditions.
In this study we aimed to use primary care records, 
linked to inpatient and mortality data, to report the 
short term, mid-term, and long term survival rates 
of people with heart failure in the community; and 
to examine trends over time by year of diagnosis, 
hospital admission around the time of diagnosis, and 
socioeconomic group.
Methods
Design and setting
We performed an open matched, retrospective 
population based cohort study using data from the 
Clinical Practice Research Datalink (CPRD) for the 
period from 1 January 2000 to 31 December 2017. 
CPRD is a primary care database containing electronic 
patient records from over 700 general practices and 
is representative of the UK population.20 At each 
consultation, symptoms or diagnoses are entered 
using a clinical coding system. Clinical observations, 
laboratory tests, prescriptions, and demographic 
details also form part of the electronic record.
We included practices in the study that had 
contributed at least one year of clinical data. Data 
quality measures included the up-to-standard date 
(which incorporates death reporting) and the patient 
acceptable flag. CPRD classifies patient records as 
“acceptable” for research purposes after a simple 
quality check to ensure that the records are as accurate 
and reliable as possible. CPRD data were linked to the 
Office for National Statistics (ONS) mortality data to 
provide the date and cause of death. The data were 
also linked to inpatient Hospital Episode Statistics 
(HES) to determine hospital admission around the 
time of diagnosis and the index of multiple deprivation 
to determine socioeconomic status. The index of 
multiple deprivation is calculated for the postal 
district of the individual’s place of residence, and 
combines information from seven domains (income, 
employment, education and training, health and 
disability, crime, barriers to housing and services, and 
living environment).21 The validity and reliability of 
the index as a measure of socioeconomic status has 
previously been reported.22
study population
We used CPRD to extract acceptable patient records 
of people aged 45 and over, registered at an up- 
to-standard practice for at least a year between 1 
January 2000 and 31 December 2017. Entry criteria 
to the cohort were a diagnostic code of heart failure in 
the primary care record and eligibility for HES and ONS 
linkage.
Patients entered the cohort on the latest of the 
following dates: 1 January 2000, date of 45th birthday, 
patient registration date plus one year, practice up-
to-standard date plus one year. We excluded patients 
with a diagnosis of heart failure that occurred before 
this date. Patients exited the cohort on the earliest 
of the following dates: 31 December 2017, patient 
transferred out date, date of death, last date of practice 
data collection, last date of available linked data.
We extracted demographic variables including 
age, sex, ethnicity, patient level deprivation (index of 
multiple deprivation), cardiovascular risk factors, and 
comorbidities for each participant. Information on 
cardiovascular risk factors (smoking, blood pressure, 
cholesterol, and body mass index) was the most 
recently recorded before the index date (the first date of 
a recorded heart failure code in the primary care record 
within the study period). Cardiovascular comorbidities 
(angina, myocardial infarction, ischaemic heart disease, 
diabetes, hypertension, stroke, atrial fibrillation, and 
valve disease) were defined by the presence of a clinical 
code at any time before the index date.
case definition
We defined heart failure cases as people with a new 
diagnosis of heart failure in their primary care record. 
The NHS terminology and classifications browser, 
the Quality and Outcomes Framework guidance, and 
ICD-10 (international classification of diseases, 10th 
revision) were used to generate a comprehensive 
list of terms to code a diagnosis of heart failure (see 
appendix 1).
We identified the first diagnosis of heart failure in 
CPRD as the earliest recorded diagnostic code in the 
general practitioner’s record within the study period 
(the index date). The time to death was measured from 
the index date. People with heart failure were matched 
by age (±5 years) and sex with up to five comparators 
registered in the same practice on the index date 
without a diagnosis of heart failure on that date (but 
they could develop the condition later).
Database linkage
Linked data were supplied directly by CPRD. The 
process used was a deterministic matching algorithm, 
which matched exactly on NHS number and on at least 
one other identifier (date of birth, sex, and postcode). 
More than 97% of HES records and 98% of ONS 
mortality data are successfully matched in this way. 
We used linked HES data to identify people 
admitted to hospital within three months of diagnosis 
(inpatient clinical code of heart failure or inpatient 
echocardiography report). This three month period 
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before or after the heart failure diagnosis was entered 
in the primary care record was chosen to allow time for 
flow of information between hospitals and practices.
Cause of death is determined by ONS according to 
the information provided on the death certificate by 
the examining doctor and is used in national statistics 
in the UK. This information is probably the most 
accurate available.23
Outcomes
The primary outcome measure was death (all cause 
mortality). We obtained the date and cause of death 
from ONS mortality data. Secondary outcomes, 
reported descriptively, included primary cause of 
death, death due to heart failure (at any position 
in the cause of death hierarchy), and death due to 
arrhythmias.
statistical analysis
We identified the number of patients with heart failure 
and presented baseline socioeconomic demographics 
for patients and matched comparators. In each group, 
we determined survival rates at one, five, 10, and 15 
years overall, for men and women, and for each 10 
year age group from age 45 and over. To investigate 
trends in mortality over time, survival at one, five, and 
10 years was determined by year of diagnosis and by 
hospital admission around the time of diagnosis. We 
investigated linear trends in survival over time by 
fitting weighted linear regression of the survival rate 
to the year of diagnosis in which the weights were 
inversely proportional to the variance of the survival 
rate. We examined socioeconomic inequalities by 
comparing median survival for people who were least 
deprived and most deprived according to the index of 
multiple deprivation. We calculated the difference in 
survival rates between the earliest and most recent 
years of diagnosis, and determined 95% confidence 
intervals using the normal distribution. To adjust 
for any changes in the age or sex structure of the 
heart failure population over time, we performed an 
additional sensitivity analysis in which survival rates 
were directly standardised by age and sex to the 2000 
population. Mixed modelling, adjusting for age, sex, 
and clustering of patients within practices, was used to 
confirm any observed association between deprivation 
and survival over time.
We used Kaplan-Meier curves and log rank tests 
to compare survival in people with and without 
heart failure, and by sex, age, and index of multiple 
deprivation. Cox proportional hazards regression 
analyses assessed the overall effect of heart failure 
on survival by adjusting for potential confounders. 
To preserve the matched study design, the initial 
adjustment for age, sex, practice, and time of diagnosis 
was performed by stratifying on matched set. Further 
adjustment allowed for index of multiple deprivation, 
ethnicity, and cardiovascular risk factors; these risk 
factors include lifestyle modifiable risk factors (body 
mass index, smoking status, systolic and diastolic 
blood pressure, total cholesterol) and medical 
history (angina, myocardial infarction, ischaemic 
heart disease, diabetes, hypertension, stroke, atrial 
fibrillation, valve disease). We tested the proportional 
hazards assumption by plotting Schoenfeld residuals 
over time. No clear trends over time were evident for 
any of the covariates in the model.
There were substantial missing data for cholesterol 
and body mass index. A comparison of the characteristics 
of people with and without missing data suggested 
the data were not missing at random. Therefore, 
we considered multiple imputation inappropriate 
and we undertook an alternative approach in which 
continuous variables were categorised and unrecorded 
data represented by an additional missing category. 
We performed a complete case analysis as a sensitivity 
analysis, with and without cholesterol and body mass 
index as covariates. Statistical analysis was carried out 
using R (version 3.5.0), with “survival” and “survminer” 
packages.24-26
Patient and public involvement
We are grateful to our two patient representatives 
who have heart failure and informed the research 
question and design for this study. They initially found 
“heart failure” a frightening term, which suggested an 
imminent demise, and were surprised to find it was 
a long term condition which they would learn to live 
with. They thought that clinical staff inadequately 
covered the issue of survival following a diagnosis, and 
they would “like doctors to have the facts” because the 
prognostic information given to them had been very 
limited. We plan to disseminate the findings of this 
research to patients, carers, heart failure charities, 
research funders, and policy makers using our social 
media platforms. We will use the hashtag “SurviveHF” 
to promote the key message of this paper within and 
beyond the heart failure community.
results
A total of 385 CPRD practices contributed data, linked 
to HES and ONS, between 1 January 2000 and 31 
December 2017. Around 58% (n=411) of practices 
within CPRD are linked to HES data. We did not include 
practices that did not report data for the study period 
or had no eligible patients. There were 2 456 338 
patients aged 45 and over who were registered for at 
least one year in the study period and were eligible for 
linkage. We identified 55 959 patients with incident 
heart failure and matched them to 278 679 controls 
(see appendix 2). In the heart failure group, 24 125 
people (43.1%) were admitted to hospital around the 
time of diagnosis overall. The percentage of patients 
who required hospital admission around the time of 
diagnosis increased between 2000 and 2007, and then 
remained stable from 2008 onwards.
Table 1 shows the baseline characteristics of patients 
with heart failure and matched comparators (and by 
admission to hospital around the time of diagnosis and 
socioeconomic status in appendix 3). The average age 
at diagnosis was 77.1 (standard deviation 10.6) overall 
and did not change over the 18 year period. Women 
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were on average almost five years older at diagnosis 
than men (79.6 v 74.8 years). The proportion of people 
with heart failure admitted to hospital around the 
time of diagnosis increased from 28.9% (n=1070) in 
2000 to 51.8% (n=1613) in 2010,and then remained 
stable. Women, older people, and patients who were 
most deprived group were admitted to hospital more 
often around the time of diagnosis. Cardiovascular 
comorbidity was common in the heart failure group 
overall, but did not vary by admission to hospital and 
index of multiple deprivation. Average blood pressure 
was lower in patients with heart failure than in the 
group without heart failure (systolic 137.5 v 139.6 
mm Hg, diastolic 76.9 v 77.6 mm Hg). Hypertension 
is a major risk factor for heart failure and a history of 
hypertension was more common in patients with heart 
failure (57.7% v 46.9%). The lower blood pressure 
in the patients with heart failure could be due to 
antihypertensive treatment or a direct consequence of 
heart failure.
cause of death
Table 2 shows the cause of death for patients with 
heart failure and for comparators. There were 30 906 
deaths in the heart failure group over the study period. 
The primary cause of death was heart failure in 2237 
table 1 | baseline characteristics of people with heart failure and matched comparators. Data are number (%) unless 
stated otherwise. sD=standard deviation
characteristic Heart failure (n=55 959) no heart failure (n=278 679)
Sex:
 Male 29 234 (52.2) 145 552 (52.2)
 Female 26 725 (47.8) 133 127 (47.8)
Age (years, mean (SD)) 77.08 (10.6) 76.08 (10.4)
Age group (years):
 45-54 1938 (3.5) 11 056 (4.0)
 55-64 5426 (9.7) 29 124 (10.5)
 65-74 12 485 (22.3) 67 851 (24.3)
 75-84 21 534 (38.5) 110 015 (39.5)
 85-94 13 453 (24.0) 57 065 (20.5)
 ≥95 1123 (2.0) 3568 (1.3)
Ethnic group:
 White 44 143 (78.9) 204 936 (73.5)
 Non-white 1497 (2.7) 6516 (2.3)
 Mixed 6585 (11.8) 38 114 (13.7)
 Missing 3734 (6.7) 29 113 (10.4)
Index of multiple deprivation (fifths):
 1 (least deprived) 10 854 (19.4) 60 020 (21.5)
 2 12 954 (23.1) 68 200 (24.5)
 3 11 947 (21.3) 58 956 (21.2)
 4 11 707 (20.9) 53 778 (19.3)
 5 (most deprived) 8447 (15.1) 37 450 (13.4)
 Missing 50 (0.1) 75 (0.1)
Smoking status:
 Never 21 252 (38.0) 123 460 (44.3)
 Former 7094 (12.7) 31 494 (11.3)
 Current 24 507 (43.8) 100 719 (36.1)
 Missing 3106 (5.6) 23 006 (8.3)
Systolic blood pressure:
 Mean (SD; mm Hg) 137.54 (21) 139.59 (18.0)
 Missing 1272 (2.3) 14 367 (5.2)
Diastolic blood pressure:
 Mean (SD; mm Hg) 76.89 (11.6) 77.64 (10.0)
 Missing 1272 (2.3) 14 367 (5.2)
Total cholesterol:
 Mean (SD; mmol/L) 4.69 (3.6) 5.03 (2.5)
 Missing 15 478 (27.7) 104 041 (37.3)
Body mass index:
 Mean (SD) 27.93 (6.1) 26.53 (4.8)
 Missing 8428 (15.1) 50 110 (18)
Medical history:
 Atrial fibrillation 14 629 (26.1) 20 910 (7.5)
 Angina 11 965 (21.4) 29 508 (10.6)
 Diabetes 13 104 (23.4) 38 824 (13.9)
 Hypertension 32 316 (57.7) 130 669 (46.9)
 Ischaemic heart disease 14 606 (26.1) 31 517 (11.3)
 Myocardial infarction 11 296 (20.2) 17 537 (6.3)
 Stroke 6271 (11.2) 19 409 (7.0)
 Valve disease 4154 (7.4) 6165 (2.2)
 Other cardiovascular disease 13 757 (24.6) 34 578 (12.4)
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(7.2%) people, but listed as any cause in 13 093 
(42.4%). Heart failure was also the primary cause of 
death in 960 (1.3%) of the no heart failure group. The 
second commonest cause of death for people with 
heart failure was respiratory disease (4925, 15.9%) 
followed by cancer (3854, 12.5%).
survival in heart failure group
Survival rates in patients with heart failure were 75.9% 
(95% confidence interval 75.5% to 76.3%) at one 
year, 45.5% (45.1 to 46.0) at five years, 24.5% (23.9 
to 25.0) at 10 years, and 12.7% (11.9 to 13.5) at 15 
years. Table 3 shows survival rates by age and sex. 
Women had worse short term and long term outcomes 
than men (one year survival 74.5% v 77.2% (P<0.001) 
and 15 year survival 11.0% v 14.1% (P<0.001)). Age at 
diagnosis was a significant determinant of subsequent 
survival.
trends in survival over time
Overall one year survival improved by 6.6% (95% 
confidence interval 4.0% to 9.2%) over time for people 
with a new diagnosis of heart failure from 74.2% 
(72.8% to 75.6%) in 2000 to 80.8% (78.6% to 83.1%) 
in 2016 (fig 1). Five year survival improved by 7.2% 
(4.2% to 10.2%) from 41.0% (39.4% to 42.7%) in 
2000 to 48.2% (45.7% to 50.7%) in 2012. Ten year 
survival improved by 6.4% (3.6% to 9.1%) from 19.8% 
(18.4% to 21.3%) in 2000 to 26.2% (24.0% to 28.6%) 
in 2007. All trends remained when survival rates were 
standardised by age and sex, and across age groups.
survival in patients admitted to hospital at time of 
diagnosis
Survival of people with heart failure admitted to 
hospital around the time of diagnosis was significantly 
worse than in those not requiring hospital admission 
(fig 2), with a median difference of 2.4 years (5.3 v 2.9 
years, log rank test, P<0.001). One year survival was 
81.2% versus 68.8%, five year survival was 51.8% 
versus 36.7%, 10 year survival was 28.8% versus 
17.8%, and 15 year survival was 15.5% versus 8.1% 
for patients not admitted to hospital and admitted to 
hospital, respectively. Survival rates by year of diagnosis 
improved more rapidly for people whose condition 
was diagnosed and managed in the community than 
for people requiring hospital admission at the time of 
diagnosis (fig 3).
socioeconomic inequalities
In patients with heart failure, there were 10 854 in the 
least deprived group and 8447 in the most deprived 
group. Overall, there was a deprivation gap of 2.4 years 
in median survival between the least deprived and most 
deprived groups (11.1 v 8.7 years, P<0.001). Figure 4 
shows the trends in survival over time by deprivation 
group. There was little difference between one and five 
year survival in the most deprived and least deprived 
groups over the study period, but 10 year survival was 
lower in the most deprived group from 2000 to 2006, 
although this gap improved in 2007. A mixed effects 
Cox model, adjusting for age, sex, year of diagnosis, 
and practice (cluster effect), indicated that the risk 
of death increased by 7% with level of deprivation 
(hazard ratio 1.07, 95% confidence interval 1.05 to 
1.09).
Overall survival
The median survival for patients with heart failure was 
18 months compared with 36 months for those without 
heart failure. Cox regression analysis suggested that 
overall patients with heart failure had a significantly 
worse prognosis than their age, sex, and practice 
matched comparators, as shown in figure 5 (hazard 
ratio 3.36, 95% confidence interval 3.31 to 3.42). An 
increased risk of death remained for patients with heart 
table 2 | cause of death in people with heart failure and age, sex, and practice matched comparators without heart 
failure. Data are number (%)
cause of death subgroup Heart failure no heart failure
Disease+s of the circulatory system 17 207 (55.7) 24 965 (32.7)
 Heart failure primary cause 2237 (7.2) 960 (1.3)
 Heart failure any cause of death* 13 093 (42.4) 5528 (7.2)
 Arrhythmias (ICD-10 codes: I47-I49) 513 (1.7) 684 (0.89)
Diseases of the respiratory system 4925 (15.9) 12 223 (16.0)
Neoplasms 3854 (12.5) 19 887 (26.0)
Diseases of the digestive system 1095 (3.5) 3526 (4.6)
Diseases of the genitourinary system 774 (2.5) 1877 (2.5)
Endocrine, nutritional, and metabolic diseases 611 (2.0) 876 (1.2)
Mental and behavioural disorders 484 (1.6) 4357 (5.7)
External causes of morbidity and mortality 438 (1.4) 1752 (2.3)
Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified 372 (1.2) 2263 (3.0)
Certain infectious and parasitic diseases 331 (1.1) 873 (1.1)
Diseases of the nervous system 318 (1.0) 2635 (3.5)
Diseases of the musculoskeletal system and connective tissue 219 (0.71) 689 (0.9)
Diseases of the skin and subcutaneous tissue 174 (0.6) 307 (0.4)
Diseases of the blood and blood-forming organs 63 (0.2) 144 (0.2)
Congenital malformations, deformations, and chromosomal abnormalities 36 (0.1) 44 (0.1)
Other 5 (0.0) 19 (0.0)
ICD-10=international classification of diseases, 10th revision.
*Includes patients for whom heart failure may have been the primary or a contributory cause of death.
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failure after adjustment for deprivation, ethnicity, and 
cardiovascular risk factors (3.05, 3.00 to 3.11). We 
observed similar results in the sensitivity analysis of 
the fully adjusted model (3.17, 3.09 to 3.26) from a 
complete case analysis of 186 285 patients; and in the 
adjusted model in which cholesterol and body mass 
index were excluded (3.02, 2.96 to 3.08, with 280 211 
patients).
discussion
Principal findings
This large community based study provides 
contemporary survival estimates for people with 
a new diagnosis of heart failure across an 18 year 
period. People admitted to hospital around the time 
of diagnosis had worse survival rates than those 
whose condition was diagnosed and managed in the 
community. Survival after heart failure diagnosis 
gradually improved over time, but more rapidly in the 
group not admitted to hospital. The deprivation gap 
in survival of 2.4 years between the least deprived 
and most deprived groups suggests socioeconomic 
inequalities in heart failure care.
strengths and limitations of study
We identified a total of 55 959 people with a new 
diagnosis of heart failure from 2000 to the end of 2017, 
which allowed reliable analyses of subgroups (year of 
diagnosis, hospital admission, and socioeconomic 
status) and recent survival trends. The data were taken 
directly from primary and secondary care sources 
with linkage between databases. ONS mortality data 
are determined by the information provided on the 
death certificate by the doctor caring for the patient 
around the time of death. Although we are aware that 
death recording in general practice can vary and death 
certification may be inaccurate in some cases, ONS 
data are the most reliable source available.23 27
In the UK, the entire population receives healthcare 
through registration with a primary care provider, 
and routinely collected data are being increasingly 
used to explore epidemiological trends.28 29 The main 
reason for primary care physicians to code medical 
information is to provide clinical care rather than 
for research purposes, and this can potentially lead 
to incomplete data. However, previous studies have 
shown that recording of diagnoses in CPRD is good,30 
as is recording of heart failure in healthcare databases 
more generally.31 We also tried to confirm primary care 
diagnoses using hospital data. Any under-reporting 
of heart failure would have diluted the observed 
association between heart failure and mortality, so we 
are confident that our overall findings are robust.
Practices using the Vision clinical system provide 
data directly to CPRD. In the past few years, CPRD 
has seen a reduction in the number of practices 
contributing data because of a decline in the popularity 
of Vision software. There is a move for CPRD to link 
with alternative clinical system providers to maintain 
the large dataset. Despite the lower number of practices 
providing data towards the end of the study period and 
a moderate level of unrecorded data being observed, 
our sensitivity analysis suggests our conclusions are 
robust.
We realise that people with pre-existing heart failure 
might be misclassified as having a new diagnosis of 
heart failure or not having the condition; however this 
misclassification is likely to be minimised by linking 
electronic data from CPRD with HES and ONS mortality 
data.32 Evidence of close agreement between heart 
table 3 | survival rates at one, five, 10, and 15 years after a diagnosis of heart failure overall and by sex and 10 year age 
group
subgroup
survival rate (% (95% ci))
at one year at five years at 10 years at 15 years
Overall 75.9 (75.5 to 76.3) 45.5 (45.1 to 46.0) 24.5 (23.9 to 25.0) 12.7 (11.9 to 13.5)
Sex:
 Male 77.2 (76.7 to 77.7) 46.9 (46.3 to 47.6) 25.8 (25.0 to 26.5) 14.1 (13.1 to 15.2)
 Female 74.5 (74.0 to 75.0) 44.0 (43.3 to 44.7) 23.0 (22.2 to 23.8) 11.0 (9.9 to 12.2)
Age group (years):
 45-54 90.3 (89.0 to 91.7) 78.5 (76.4 to 80.6) 64.7 (61.6 to 68.0) 54.4 (50.0 to 59.3)
 55-64 87.9 (87.0 to 88.8) 70.6 (69.3 to 72.0) 52.8 (50.9 to 54.7) 38.4 (35.6 to 41.5)
 65-74 83.5 (82.8 to 84.1) 59.1 (58.1 to 60.1) 35.4 (34.2 to 36.6) 17.2 (15.5 to 19.2)
 75-84 76.5 (76.0 to 77.1) 43.2 (42.4 to 44.0) 18.4 (17.6 to 19.2) 5.8 (4.9 to 7.0)
 85-94 63.2 (62.4 to 64.1) 22.3 (21.4 to 23.2) 4.4 (3.8 to 5.2) 0.2 (0.04 to 1.4)
 ≥95 43.9 (41.0 to 47.1) 6.0 (4.4 to 8.3) — —
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Fig 1 | survival rates at one, five, and 10 years for people with heart failure by year of 
diagnosis
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failure incidence in CPRD with population surveillance 
studies has also been found.33 We were unable to 
identify the type of heart failure (reduced or preserved 
ejection fraction) in this study, which would have been 
desirable because of the differences in management 
depending on ejection fraction. We hope this will be 
possible in the future when echocardiography coding 
becomes more sophisticated and codes for heart failure 
with preserved ejection are increasingly used.
Heart failure was listed as a cause of death in less 
than half of the people with the condition. Other 
cardiovascular diseases, respiratory disorders, and 
cancer were also common causes of death in people 
diagnosed as having heart failure. People with 
heart failure are often living with several long term 
conditions; a large study using UK data found that 
79% of people with heart failure had three or more 
comorbidities.4 Cardiovascular diseases, particularly 
atrial fibrillation, diabetes, ischaemic heart disease, 
and stroke, were the most common comorbidities. 
Other diseases including cancer (25%), chronic 
kidney disease (24%), and depression (22%) were 
prevalent and comorbidities occurred at a younger 
age in deprived populations with heart failure. In the 
no heart failure group, heart failure was listed as the 
primary cause of death in 1.3%. This finding probably 
relates to people who developed acute heart failure 
and died soon afterwards; therefore, they did not 
have a diagnosis in their primary care record. In the 
most recent National Heart Failure audit, inhospital 
mortality was 9.4%.10
Multimorbidity (two or more long term conditions) 
can make the diagnosis of heart failure difficult 
because symptoms overlap and management is more 
challenging. Two thirds of people with heart failure 
have three or more other long term conditions.4 In our 
study, the average age of diagnosis in primary care 
was 77, therefore survival after diagnosis is unlikely 
to depend on heart failure care alone. Holistic, person 
centred care is required to optimally manage people 
with heart failure in the context of multimorbidity, with 
a focus on quality of life as well as length of survival.
Our study did not explore the effect of drugs, devices, 
or transplantation on the survival of people with 
heart failure. The aim was to present contemporary 
short term, mid-term, and long term survival rates 
at a population level, and to explore trends over 
time. Further research exploring new treatments, 
technologies, guidelines, and health policies is also 
needed to understand their impact at the patient level.
comparison with other studies
There is considerable variation in previous heart 
failure survival estimates depending on the study 
setting. People with acute heart failure recruited from 
hospital inpatient populations have comparatively 
poor outcomes. Among 12 440 people with heart 
failure in the European Society of Cardiology Heart 
Failure Long-Term registry, one year mortality was 
23.6% for people with acute heart failure and 6.4% 
for those with chronic heart failure across Europe.34 
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Fig 2 | Kaplan-Meier curve of survival for people with a new diagnosis of heart failure 
who were admitted to hospital or not admitted to hospital at time of diagnosis and for 
comparators matched by age, sex, and practice
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Fig 3 | survival at one, five, and 10 years in patients with heart failure not requiring 
hospital admission and requiring hospital admission around time of diagnosis by year 
of diagnosis
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Despite initiatives in many countries to improve 
care for people with heart failure, success has been 
limited. The most recent annual national heart failure 
audit in England reported one year mortality rates of 
29.6% among people admitted to hospital with heart 
failure. This rate had not improved for the previous six 
years despite service restructuring to provide patients 
with care from specialist heart failure teams during 
admission and immediately after discharge.10
Population based studies, such as the Framingham 
or the Echocardiographic Heart of England Screening 
study, have reported long term survival for people 
with heart failure, but participants were invited for 
screening rather than presenting to primary care 
with symptoms.11 35 In the Echocardiographic Heart 
of England Screening study cohort, five and 10 year 
survival rates of people with heart failure were 53% 
and 27%, but diagnosis at screening could represent 
an earlier disease stage.35 Several European countries 
have established registries using routinely collected 
healthcare data to monitor trends in long term 
conditions. In Sweden, among 88 038 people with 
heart failure, overall five year survival was 48% and 
survival rates improved by 19% between 2006 and 
2010.14
Our previous study explored survival rates in The 
Health Improvement Network database between 1998 
and 2012, without HES or index of multiple deprivation 
linkage, and found no improvement in survival over 
that period.13 This conclusion was of concern to the 
heart failure community and we wanted to conduct 
a further analysis using a different dataset linked to 
hospital and deprivation data to verify and explore 
the findings. In this CPRD study, we have provided 
contemporary survival rates up to 2017, which have 
shown a modest improvement since 2000. We have 
also been able to analyse survival related to hospital 
admission around the time of diagnosis and among 
socioeconomic groups. This analysis has highlighted 
the importance of timely diagnosis in primary care 
and the gap in survival between the most deprived and 
least deprived groups.
conclusions and policy implications
In this study we found gradual improvements in 
survival rates over time, which is encouraging. 
However, the outlook after a new diagnosis of heart 
failure, particularly for those requiring admission to 
hospital, remains poor. Hospital admission at the time 
of diagnosis probably relates to a more advanced stage 
of disease. Lead time bias might also be a contributory 
factor; patients with an earlier diagnosis appear to 
live longer. Earlier diagnosis in primary care, however, 
does allow treatment initiation, potentially avoiding 
emergency admission to hospital and improving patient 
outcomes.
Heart failure has not been a priority area in 
government policy or funding, and other serious 
conditions, such as cancer, have seen a much greater 
improvement in survival over time.36 However, in 2006 
a heart failure indicator was introduced to the Quality 
and Outcomes Framework for general practitioners in 
England. The indicator aimed to incentivise general 
practitioners to use echocardiography to support 
diagnosis and initiation of angiotensin converting 
enzyme inhibitors and β blockers for people with an 
ejection fraction below 40%. We could not establish 
the direct effect of this indicator on our data, but the 
10 year survival difference between the least deprived 
and most deprived groups, observed in previous years, 
became non-significant in 2007. Future work is needed 
to monitor the trends in long term survival since the 
new indicator was introduced.
There has been a sustained improvement in 
cancer survival rates following the introduction of 
the Cancer Plan in 2000, which included investment 
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Fig 5 | Kaplan-Meier curve of overall survival for people with a new diagnosis of heart 
failure and comparators matched by age, sex, and practice
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and infrastructure changes to improve diagnosis 
and treatment.37 The lack of substantial progress in 
improving heart failure survival rates should alert 
policy makers to the need for further investment in 
heart failure services. Improved general practitioners 
access to diagnostics such as natriuretic peptide 
testing, rapid referral pathways (such as the “two week 
wait cancer” pathways) for echocardiography, and 
specialist assessment and early treatment initiation 
might be areas for improvement. Primary care led 
research is also needed to understand the complexity 
of heart failure diagnosis and management in the 
community, and to develop and test new strategies to 
achieve better outcomes for patients.
This work uses data provided by patients and collected by the NHS 
as part of their care and support and would not have been possible 
without access to these data. The National Institute for Health 
Research recognises and values the role of patient data, securely 
accessed and stored, in underpinning and leading to improvements in 
research and care. HES and ONS data are subject to copyright (2018) 
and can be re-used with the permission of The Health and Social Care 
Information Centre. All rights reserved.
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